

Special Issue

Protoparvoviruses: Friends or Foes?

Message from the Guest Editors

Accumulating evidence has demonstrated that some members of the *Parvoviridae* family, in particular some *rodent Protoparvoviruses* have natural anticancer activities, while being nonpathogenic to humans. However, a number of Parvoviruses cause diseases in humans and animals and recently, deep sequencing and metagenomic techniques have allowed the discovery of several novel parvoviruses, suspected of being pathogenic; in particular bufaviruses. This Special Issue of *Viruses* will explore the impact of Protoparvovirus evolution on the outcome of the interactions of these agents with host cells and organisms. Topics may include studies on various steps of the viral cycle, virus adaptation, immune responses to infection and mechanisms of virus immune evasion, clinical presentation of virus infection, and strategies for vaccine development. *Dr. Jürg Nüesch* Guest editors

Guest Editors

Dr. Christiane Dinsart

DKFZ, Abt F010, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany

Dr. Jürg P.F. Nüesch

Infection, Inflammation and Cancer (IIC), Department Virus-Associated Carcinogenesis (F170) German Cancer Research Center (DKFZ), Heidelberg, Germany

Deadline for manuscript submissions

closed (31 January 2018)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/8656

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).